Exploring how MARCH9 helps fight HIV-1 infection
Understanding the Antiviral Mechanism of MARCH9
This study is looking at how a protein called MARCH9 can help lower the ability of HIV-1 to infect cells, which could lead to new and better treatments for people living with HIV.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Buffalo NIH-funded |
| Lab location | 1 site (Amherst, United States) |
| Project ID | NIH-11009319 on NIH RePORTER |
What this research studies
This research investigates the role of a protein called MARCH9 in reducing the infectivity of HIV-1, the virus responsible for AIDS. By studying how MARCH9 interacts with immune cells and affects the production of viral proteins, the research aims to uncover new therapeutic targets that could lead to more effective treatments for HIV. The approach involves detailed laboratory experiments to understand the mechanisms by which MARCH9 operates without harming the immune cells. This could provide insights into developing novel antiviral strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV-1 who are seeking new treatment options.
Not a fit: Patients who are not infected with HIV-1 or those who are already responding well to existing antiretroviral therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments for HIV-1 that are more effective and have fewer side effects than current therapies.
How similar studies have performed: Other research has shown promise in targeting host proteins to combat HIV, suggesting that this approach could yield valuable insights.
Where this research is happening
Amherst, United States
- State University of New York at Buffalo — Amherst, United States (Active)
Researchers
- Principal investigator: D'angelo, Mary Rose — State University of New York at Buffalo
- Study coordinator: D'angelo, Mary Rose
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.